Last reviewed · How we verify
NCT05687461
Construction of a National Diagnosis and Treatment Quality Control Platform for Major Respiratory Diseases
trial testing Build a national diagnosis and treatment quality control platform for major respiratory diseases in Quality Control in 10,000 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | China-Japan Friendship Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 10,000 |
| Start date | 1 July 2022 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 July 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Build a national diagnosis and treatment quality control platform for major respiratory diseases
Conditions studied
- Quality Control — all drugs for Quality Control →
Sponsor
China-Japan Friendship Hospital
Who can join
Eligibility, any sex, with Quality Control. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
1. Build a national diagnosis and treatment quality control platform for major respiratory diseases It will establish and improved a "National diagnosis and Treatment quality control Platform for major respiratory diseases", and form a three-level network of diagnosis and treatment quality control for major respiratory diseases with a three-level system structure of "national, provincial and hospital". 2. Promote standardized diagnosis and treatment techniques for major respiratory diseases Relying on the specialized disease collaboration group or innovative unit model, all-round and hierarchical precision training and teaching are carried out to popularize and promote standardized diagnosis and treatment technology schemes for major respiratory diseases, so as to achieve the homogenization of diagnosis and treatment level for major respiratory diseases.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05687461
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Quality Control
Currently open trials in the same condition.
- NCT07524998 — A Chinese Multicenter Study on Surgical Techniques and Outcomes Across the Lifespan in Congenital Heart Disease · recruiting
Other China-Japan Friendship Hospital trials
Trials by the same sponsor.
- NCT07482995 — Effects of Baduanjin Exercise on Improving Health in Sedentary Young and Middle-Aged Adults · NA · not yet recruiting
- NCT07406932 — A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial L · NA · not yet recruiting
- NCT07509775 — Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis (AS): A Cohort Study Protocol Focusing on · recruiting
- NCT07339956 — Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents · EARLY_PHASE1 · not yet recruiting
- NCT07280429 — ICIAM Rehabilitation Program Study: A Randomized Controlled Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05687461 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by China-Japan Friendship Hospital
- Last refreshed: 18 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05687461.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing